Sign inJoin waitlistJoin the waitlist

Kevin Ginn

Director, Brain Tumor Program, Pediatric Hematology · University of Kansas School of Medicine

Credentials: · · · · · ·

History

Children's Mercy Hospital
2020–Present

Pediatric Hematology/Oncology
Children's Mercy Hospital
2008–2011
Pediatrics
2005–2008
Med Univ of South Carolina Coll of Med
2001–2005

Research

Atypical teratoid rhabdoid tumor: current therapy and future directions
Frontiers in Oncology · 2012 · First of 2 authors · 144 citations
Choroid plexus carcinoma in children: the Head Start experience
Pediatric Blood & Cancer · 2015 · 38 citations
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology · 2023 · 30 citations

Melissa Gener
6 papers
LC
Linda Cooley
4 papers
Midhat Farooqi
4 papers
Amar Gajjar
3 papers
David Limbrick
3 papers
Eric Jackson
3 papers
James Johnston
3 papers
JF
Jonathan Finlay
3 papers
Joshua Chern
3 papers
Kathleen Dorris
3 papers
Lindsay Kilburn
3 papers
Robert Naftel
3 papers

Clinical trials

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Milton S. Hershey Medical Center
2024–2035
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Site PI · Recruiting · Phase 1, Phase 2
PedAL BCU, LLC
2022–2030
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
Children's Oncology Group
2022–2026
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Site PI · Recruiting · Phase 2
Giselle Sholler
2021–2029